Drug Trial Radar · NCT03422822
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,166
Actual
Start
Mar 8, 2018
Primary completion
Dec 22, 2025
Study completion Dec 22, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study. The efficacy and safety of two dosage strengths of Abrocitinib, 100 mg and 200 mg taken orally once daily, will be evaluated over variable lengths of study participation. The study consists of a 92 week initial treatment period followed by a variable length secondary treatment period during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country. The B7451015 study also includes a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI. The sub-study will be conducted in selected countries at selected sites. Eligible subjects are those who were 12 to \<18 years of age at the screening visit of the qualifying parent study and who are currently participating in the main B7451015 study. The sub-study will include serial Magnetic Resonance Imaging (MRI) annually and continue until all enrolled subjects are 18 years of age and have been imaged at least once or have discontinued/withdrawn.
Conditions
- Dermatitis, Atopic
Interventions
Abrocitinib 100 mgDrug
In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
Abrocitinib 200 mgDrug
In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
PlaceboDrug
For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
Abrocitinib 100 mgDrug
For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
Abrocitinib 100 mgDrug
In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
Abrocitinib 200 mgDrug
In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse eventsTime frame: Throughout study regardless of availability of commercial product until at least 2024, or until the sponsor terminates the study; an estimated maximum of 8 years
- Serious adverse events and adverse events leading to discontinuationTime frame: Throughout study regardless of availability of commercial product until at least 2024, or until the sponsor terminates the study; an estimated maximum of 8 years
- Change from baseline in clinical laboratory valuesTime frame: Throughout study regardless of availability of commercial product until at least 2024, or until the sponsor terminates the study; an estimated maximum of 8 years
- Change from baseline in electrocardiogram (ECG) measurementsTime frame: Throughout study regardless of availability of commercial product until at least 2024, or until the sponsor terminates the study; an estimated maximum of 8 years
- Change from baseline in vital signsTime frame: Throughout study regardless of availability of commercial product until at least 2024, or until the sponsor terminates the study; an estimated maximum of 8 years
Locations
539 sites in 28 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama
Clinical Research Center of Alabama, LLC
Birmingham, Alabama
University of Alabama at Birmingham - Dermatology Research Clinic
Birmingham, Alabama
University of Alabama at Birmingham Hospital Outreach Lab
Birmingham, Alabama
Clinical Research Center of Alabama, LLC
Birmingham, Alabama
The University of Alabama at Birmingham, Department of Dermatology
Birmingham, Alabama
Emmaus Research Center, Inc.
Anaheim, California
California Dermatology & Clinical Research Institute
Encinitas, California
First OC Dermatology Research Inc
Fountain Valley, California
Marvel Research, LLC
Huntington Beach, California
Tilda Research Inc.
Irvine, California
Beach Allergy and Asthma Specialty Group, A Medical Corporation
Long Beach, California
Keck School of Medicine of University of Southern California
Los Angeles, California
Wallace Medical Group, Inc
Los Angeles, California
Allergy & Asthma Associates of Southern California dba Southern California Research
Mission Viejo, California
Dermatology Specialists, Inc.
Oceanside, California
Peninsula Headlands LLC
Rolling Hills Estates, California
UC Davis Health
Sacramento, California
MedDerm Associates
San Diego, California
University of California San Diego Dermatology
San Diego, California
Synergy Dermatology
San Francisco, California
San Luis Dermatology and Laser Clinic
San Luis Obispo, California
Southern California Dermatology, Inc.
Santa Ana, California
Wolverine Clinical Trials, Llc
Santa Ana, California
Mosaic Dermatology
Santa Monica, California
Clinical Science Institute
Santa Monica, California
Asthma and Allergy Associates, PC
Colorado Springs, Colorado
Colorado Springs Dermatology Clinic, PC
Colorado Springs, Colorado
Skin Care Research
Boca Raton, Florida
Renaissance Research and Medical Group, Inc
Cape Coral, Florida
Florida Academic Centers Research and Education, LLC
Coral Gables, Florida
Skin Research Institute
Coral Gables, Florida
Moonshine Research Center, Inc.
Doral, Florida
Homestead Research Institute
Homestead, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Solutions Through Advanced Research, Inc.
Jacksonville, Florida
C & R Research Services USA, Inc
Kendall, Florida
Clinical Trials Solutions
Miami, Florida
Global Health Clinical Trials Corp
Miami, Florida
Baumann Cosmetic and Research Institute
Miami, Florida
Showing 40 of 539 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.